Issue Archive
Table of Contents
INSIDE BLOOD COMMENTARIES
Looking up for AML in Down syndrome
Clinical Trials & Observations
In this issue of Blood, Taub et al report improved survival with reduced-intensity therapy and the prognostic significance of end-induction residual disease from the largest prospective trial to date in children with myeloid leukemia of Down syndrome (ML-DS): the Children’s Oncology Group AAML0431 study.1
Down syndrome and AML: where do we go from here?
Clinical Trials & Observations
It is well documented that young children with Down syndrome (DS) have both a 500-fold increased incidence of acute myeloid leukemia (ML-DS) and a decreased tolerance of intensive chemotherapy. In this issue of Blood, Uffmann et al present the results of a large, multicentered, international, nonrandomized trial reducing the etoposide exposure while preserving the excellent outcomes reported in previous trials.1 This trial builds on international experience demonstrating that most young children with ML-DS may be cured with less intensive therapy, and confirms that there remains a significant subset of patients for whom we have limited therapeutic options.
Equal opportunity CAR T cells
Clinical Trials & Observations
In this issue of Blood, Gardner et al report results of a phase 1 trial of 45 children and young adults with relapsed or refractory B-lineage acute lymphoblastic leukemia (ALL) who received a T-cell product of defined CD4/CD8 composition that was genetically modified with a CD19-4-1BB:ζ chimeric antigen receptor (CAR) lentiviral vector.1
Human megakaryocytes: finding the root
In this issue of Blood, Miyawaki et al identify the most primitive progenitor cell population that makes only megakaryocytes and platelets in adult humans and show it is expanded in myeloproliferative neoplasms such as essential thrombocythemia (ET).1 Approximately 1011 platelets are produced on a daily basis in humans, but their exact journey from undifferentiated hematopoietic stem cells (HSCs) is still highly debated. Platelets have the shortest half-life of all blood components and are rapidly recruited when injury occurs, yet have long been thought to be among the cell types to be specified as the furthest from the HSCs in the hematopoietic hierarchy. For several decades, it was understood that differentiation proceeds by a series of binary fates choices, in particular with a common myeloid progenitor (CMP) downstream of HSCs that would give rise to a restricted myeloid progenitor (granulocyte-macrophage progenitor) and to a megakaryocyte-erythrocyte progenitor (MEP). Only downstream of MEPs would unilineage megakaryocyte and unilineage erythrocyte progenitors arise. Recently though, several groups have reported that megakaryocyte and platelet production may not follow this strict hierarchical branching path. Instead, committed megakaryocyte precursors could be found much earlier, either within the HSC2,-4 or the multipotent progenitor compartment.5 An early precursor that exclusively produces human megakaryocytes in humans, however, had not been described.
EPCR: a novel marker of cultured cord blood HSCs
In this issue of Blood, Fares et al1 demonstrate that endothelial protein C receptor (EPCR) is a reliable marker of human cord blood (CB) hematopoietic stem cells (HSCs), both from uncultured cells and those expanded with UM171, a pyrimidoindole derivative previously shown to expand CB HSCs.2
Activated kinases in ALL: time to act
In this issue of Blood, Reshmi et al1 report a study that defines a protocol for identifying kinase-driven high-risk (HR) features, known as “Ph-like” expression profile, in patients with acute lymphocytic leukemia (ALL). Revealing the underlying genetic aberration allows better prognostication and may point to potential therapeutic options for specific patients. Originally identified in pediatric patients, this Ph-like or kinase-driven ALL (KD-ALL) subtype has also been found to be common among adults.2,3 The journey to the routine identification of these kinase-activating genetic alternations started 8 years ago and required extensive efforts and use of different laboratory methods to become feasible. The most important take-home message from this work is that the time has come for routine screening for kinase-activating alterations in ALL. Although this study is published before clinical outcome data of the patients enrolled in the Children’s Oncology Group study have matured, the clinical significance of identification of KD-ALL is well established.4 Reshmi et al confirm the complexity of the genetic alteration map of these potentially targetable aberrations. The authors also provide a working diagnostic paradigm starting with a simple gene expression screening test, which reliably identifies patients in whom genetic testing for kinase-activating alterations is futile. Of 202 patients whose suggested score for screening was below 0.5, only in 1 was a potentially targetable fusion detected (HOOK3-FGFR1 genes).
Now I cuss less about ICUS
In this issue of Blood, Malcovati et al show that somatic mutations can identify patients with unexplained cytopenias who have, or are at a high risk of developing, myeloid malignancies. This study provides clear evidence that supports integration of gene-panel sequencing into routine clinical evaluation of unexplained cytopenias.1
HOW I TREAT
CLINICAL TRIALS AND OBSERVATIONS
Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial
Clinical Trials & Observations
Publisher's Note: There is an Inside Blood Commentary on this article in this issue.
Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial
Clinical Trials & Observations
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Clinical Trials & Observations
Publisher's Note: There is an Inside Blood Commentary on this article in this issue.
HEMATOPOIESIS AND STEM CELLS
Identification of unipotent megakaryocyte progenitors in human hematopoiesis
Publisher's Note: There is an Inside Blood Commentary on this article in this issue.
EPCR expression marks UM171-expanded CD34+ cord blood stem cells
Publisher's Note: There is an Inside Blood Commentary on this article in this issue.
LYMPHOID NEOPLASIA
Targetable kinase gene fusions in high-risk B-ALL: a study from the Children’s Oncology Group
Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax
Clinical Trials & Observations
MYELOID NEOPLASIA
Clinical significance of somatic mutation in unexplained blood cytopenia
Clinical Trials & Observations
Publisher's Note: There is an Inside Blood Commentary on this article in this issue.
THROMBOSIS AND HEMOSTASIS
Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin
Clinical Trials & Observations
LETTERS TO BLOOD
BLOOD WORK
-
Cover Image
Cover Image
Cytospin preparation after 7-day culture of the novel human megakaryocyte progenitor (MegP) in liquid medium (May-Giemsa staining). Progeny of MegPs have distinct morphological features of megakaryocytes, such as polyploidy and bleb formation. See the article by Miyawaki et al on page 3332.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals